PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project-Reference-Cited by-同舟云学术

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

Published:2021-01 Issue: Volume:151 Page:69-75
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Blons H.^ORCID,Oudart J.-B.,Merlio J.-P.^ORCID,Debieuvre D.,de Fraipont F.,Audigier-Valette C.,Escande F.,Hominal S.,Bringuier P.‐P.^ORCID,Fraboulet-Moreau S.,Ouafik L.^ORCID,Moro-Sibilot D.,Lemoine A.,Langlais A,Missy P.,Morin F.,Souquet P.-J.,Barlesi F.,Cadranel J.,Beau‐Faller M.

Funder

French Cooperative Thoracic Intergroup

Institut National du Cancer

AstraZenaca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010

3. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010